Ligand Pharmaceuticals Inc has a consensus price target of $113.8, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Benchmark, and HC Wainwright & Co. on February 29, 2024, December 13, 2023, and September 19, 2023. With an average price target of $127.67 between HC Wainwright & Co., Benchmark, and HC Wainwright & Co., there's an implied 74.58% upside for Ligand Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/29/2024 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 96.91% | HC Wainwright & Co. | Joseph Pantginis | → $144 | Reiterates | Buy → Buy | Get Alert |
12/13/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 29.91% | Benchmark | Robert Wasserman | → $95 | Reiterates | Buy → Buy | Get Alert |
09/19/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 96.91% | HC Wainwright & Co. | Joseph Pantginis | → $144 | Reiterates | Buy → Buy | Get Alert |
08/23/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 29.91% | Benchmark | Robert Wasserman | → $95 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 96.91% | HC Wainwright & Co. | Joseph Pantginis | → $144 | Reiterates | Buy → Buy | Get Alert |
07/25/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 50.42% | Barclays | Balaji Prasad | $120 → $110 | Maintains | Overweight | Get Alert |
06/02/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 96.91% | HC Wainwright & Co. | Joseph Pantginis | $135 → $144 | Reiterates | Buy → Buy | Get Alert |
02/21/2023 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 29.91% | Benchmark | Robert Wasserman | → $95 | Reiterates | → Buy | Get Alert |
12/23/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 23.07% | Roth Capital | Scott Henry | $85 → $90 | Maintains | Buy | Get Alert |
11/21/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 64.09% | Barclays | Balaji Prasad | $150 → $120 | Maintains | Overweight | Get Alert |
10/25/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 105.12% | Barclays | Balaji Prasad | $157 → $150 | Maintains | Overweight | Get Alert |
09/02/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 139.31% | Roth Capital | Scott Henry | $185 → $175 | Maintains | Buy | Get Alert |
07/05/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 114.69% | Barclays | Balaji Prasad | $165 → $157 | Maintains | Overweight | Get Alert |
05/16/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 77.77% | Stephens & Co. | Jacob Johnson | $153 → $130 | Maintains | Overweight | Get Alert |
02/22/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 77.77% | Benchmark | Robert Wasserman | $180 → $130 | Maintains | Buy | Get Alert |
02/18/2022 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 125.63% | Barclays | Balaji Prasad | $185 → $165 | Maintains | Overweight | Get Alert |
09/22/2021 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 146.14% | Barclays | Balaji Prasad | — | Maintains | Overweight | Get Alert |
07/30/2021 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 159.82% | Roth Capital | Scott Henry | — | Maintains | Buy | Get Alert |
05/04/2021 | LGND | Buy Now | Ligand Pharmaceuticals | $73.13 | 159.82% | Barclays | Balaji Prasad | — | Maintains | Overweight | Get Alert |
The latest price target for Ligand Pharmaceuticals (NASDAQ: LGND) was reported by HC Wainwright & Co. on February 29, 2024. The analyst firm set a price target for $144.00 expecting LGND to rise to within 12 months (a possible 96.91% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Ligand Pharmaceuticals (NASDAQ: LGND) was provided by HC Wainwright & Co., and Ligand Pharmaceuticals reiterated their buy rating.
There is no last upgrade for Ligand Pharmaceuticals.
There is no last downgrade for Ligand Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a reiterated with a price target of $0.00 to $144.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $73.13, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.